FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006771562> ?p ?o ?g. }

• W3006771562 endingPage "560.e3" @default.
• W3006771562 startingPage "552" @default.
• W3006771562 abstract "ObjectiveTo determine whether antioxidants improve male fertility, as measured by semen parameters and DNA fragmentation at 3 months and pregnancy resulting in live birth after up to 6 months of treatment, among couples with male factor infertility.DesignMulticenter, double-blind, randomized, placebo-controlled trial with an internal pilot study.SettingNine fertility centers in the United States from December 2015 to December 2018.Patient(s)Men (N = 174) with sperm concentration ≤15 million/mL, motility ≤40%, normal morphology ≤4%, or DNA fragmentation >25%, and female partners who were ovulatory, ≤40 years old, and had documented tubal patency.Intervention(s)Males randomly assigned to receive an antioxidant formulation (n = 85) containing 500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of l-carnitine, 20 mg of zinc, 1,000 μg of folic acid, 10 mg of lycopene daily, or placebo (n = 86). Treatment lasted for a minimum of 3 months and maximum of 6 months, and couples attempted to conceive naturally during the first 3 months and with clomiphene citrate with intrauterine insemination of the female partner in months 4 through 6.Main Outcome Measure(s)Primary outcome was live birth; secondary outcomes included pregnancy within 6 months of treatment. For the internal pilot, the primary outcomes were semen parameters and sperm DNA fragmentation index after 3 months of treatment.Result(s)In the Males, Antioxidants, and Infertility (MOXI) study, after 3 months of treatment, the change in sperm concentration differed between the antioxidant group (median −4.0 [interquartile range−12.0, 5.7] million/mL) and placebo group (+2.4 [−9.0, 15.5] million/mL). However, there were no statistically significant differences between the two groups for changes in sperm morphology, motility, or DNA fragmentation. Among the 66 oligospermic men at randomization, sperm concentration did not differ at 3 months between the antioxidant and control groups: 8.5 (4.8, 15.0) million/mL versus 15.0 (6.0, 24.0) million/mL. Of the 75 asthenospermic men, motility did not differ at 3 months: 34% ± 16.3% versus 36.4% ± 15.8%. Among the 44 men with high DNA fragmentation, DNA fragmentation did not differ at 3 months: 29.5% (21.6%, 36.5%) versus 28.0% (20.6%, 36.4%). In the entire cohort, cumulative live birth did not differ at 6 months between the antioxidant and placebo groups: 15% versus 24%.Conclusion(s)Antioxidants do not improve semen parameters or DNA integrity among men with male factor infertility. Although limited by sample size, this study suggests that antioxidant treatment of the male partner does not improve in vivo pregnancy or live-birth rates.Clinical Trial Registration NumberNCT02421887 To determine whether antioxidants improve male fertility, as measured by semen parameters and DNA fragmentation at 3 months and pregnancy resulting in live birth after up to 6 months of treatment, among couples with male factor infertility. Multicenter, double-blind, randomized, placebo-controlled trial with an internal pilot study. Nine fertility centers in the United States from December 2015 to December 2018. Men (N = 174) with sperm concentration ≤15 million/mL, motility ≤40%, normal morphology ≤4%, or DNA fragmentation >25%, and female partners who were ovulatory, ≤40 years old, and had documented tubal patency. Males randomly assigned to receive an antioxidant formulation (n = 85) containing 500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of l-carnitine, 20 mg of zinc, 1,000 μg of folic acid, 10 mg of lycopene daily, or placebo (n = 86). Treatment lasted for a minimum of 3 months and maximum of 6 months, and couples attempted to conceive naturally during the first 3 months and with clomiphene citrate with intrauterine insemination of the female partner in months 4 through 6. Primary outcome was live birth; secondary outcomes included pregnancy within 6 months of treatment. For the internal pilot, the primary outcomes were semen parameters and sperm DNA fragmentation index after 3 months of treatment. In the Males, Antioxidants, and Infertility (MOXI) study, after 3 months of treatment, the change in sperm concentration differed between the antioxidant group (median −4.0 [interquartile range−12.0, 5.7] million/mL) and placebo group (+2.4 [−9.0, 15.5] million/mL). However, there were no statistically significant differences between the two groups for changes in sperm morphology, motility, or DNA fragmentation. Among the 66 oligospermic men at randomization, sperm concentration did not differ at 3 months between the antioxidant and control groups: 8.5 (4.8, 15.0) million/mL versus 15.0 (6.0, 24.0) million/mL. Of the 75 asthenospermic men, motility did not differ at 3 months: 34% ± 16.3% versus 36.4% ± 15.8%. Among the 44 men with high DNA fragmentation, DNA fragmentation did not differ at 3 months: 29.5% (21.6%, 36.5%) versus 28.0% (20.6%, 36.4%). In the entire cohort, cumulative live birth did not differ at 6 months between the antioxidant and placebo groups: 15% versus 24%. Antioxidants do not improve semen parameters or DNA integrity among men with male factor infertility. Although limited by sample size, this study suggests that antioxidant treatment of the male partner does not improve in vivo pregnancy or live-birth rates." @default.
• W3006771562 created "2020-03-06" @default.
• W3006771562 creator A5005306051 @default.
• W3006771562 creator A5026947637 @default.
• W3006771562 creator A5037540780 @default.
• W3006771562 creator A5038223232 @default.
• W3006771562 creator A5038439301 @default.
• W3006771562 creator A5039468733 @default.
• W3006771562 creator A5045463023 @default.
• W3006771562 creator A5053242908 @default.
• W3006771562 creator A5060972453 @default.
• W3006771562 creator A5067274433 @default.
• W3006771562 creator A5069339514 @default.
• W3006771562 creator A5073984510 @default.
• W3006771562 creator A5074289517 @default.
• W3006771562 creator A5077246875 @default.
• W3006771562 creator A5086164230 @default.
• W3006771562 creator A5086459592 @default.
• W3006771562 creator A5088388829 @default.
• W3006771562 date "2020-03-01" @default.
• W3006771562 modified "2023-10-16" @default.
• W3006771562 title "The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial" @default.
• W3006771562 cites W1532901402 @default.
• W3006771562 cites W1963895424 @default.
• W3006771562 cites W1966316717 @default.
• W3006771562 cites W1967977701 @default.
• W3006771562 cites W1990841712 @default.
• W3006771562 cites W1994291765 @default.
• W3006771562 cites W1995116906 @default.
• W3006771562 cites W2015192276 @default.
• W3006771562 cites W2015700527 @default.
• W3006771562 cites W2038885586 @default.
• W3006771562 cites W2041849093 @default.
• W3006771562 cites W2052999816 @default.
• W3006771562 cites W2131093877 @default.
• W3006771562 cites W2155740052 @default.
• W3006771562 cites W2169474580 @default.
• W3006771562 cites W2228555604 @default.
• W3006771562 cites W2311311479 @default.
• W3006771562 cites W2336599910 @default.
• W3006771562 cites W2766252936 @default.
• W3006771562 cites W2893885083 @default.
• W3006771562 cites W2897789566 @default.
• W3006771562 cites W2898581013 @default.
• W3006771562 doi "https://doi.org/10.1016/j.fertnstert.2019.11.008" @default.
• W3006771562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7219515" @default.
• W3006771562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32111479" @default.
• W3006771562 hasPublicationYear "2020" @default.
• W3006771562 type Work @default.
• W3006771562 sameAs 3006771562 @default.
• W3006771562 citedByCount "107" @default.
• W3006771562 countsByYear W30067715622020 @default.
• W3006771562 countsByYear W30067715622021 @default.
• W3006771562 countsByYear W30067715622022 @default.
• W3006771562 countsByYear W30067715622023 @default.
• W3006771562 crossrefType "journal-article" @default.
• W3006771562 hasAuthorship W3006771562A5005306051 @default.
• W3006771562 hasAuthorship W3006771562A5026947637 @default.
• W3006771562 hasAuthorship W3006771562A5037540780 @default.
• W3006771562 hasAuthorship W3006771562A5038223232 @default.
• W3006771562 hasAuthorship W3006771562A5038439301 @default.
• W3006771562 hasAuthorship W3006771562A5039468733 @default.
• W3006771562 hasAuthorship W3006771562A5045463023 @default.
• W3006771562 hasAuthorship W3006771562A5053242908 @default.
• W3006771562 hasAuthorship W3006771562A5060972453 @default.
• W3006771562 hasAuthorship W3006771562A5067274433 @default.
• W3006771562 hasAuthorship W3006771562A5069339514 @default.
• W3006771562 hasAuthorship W3006771562A5073984510 @default.
• W3006771562 hasAuthorship W3006771562A5074289517 @default.
• W3006771562 hasAuthorship W3006771562A5077246875 @default.
• W3006771562 hasAuthorship W3006771562A5086164230 @default.
• W3006771562 hasAuthorship W3006771562A5086459592 @default.
• W3006771562 hasAuthorship W3006771562A5088388829 @default.
• W3006771562 hasBestOaLocation W30067715621 @default.
• W3006771562 hasConcept C119060515 @default.
• W3006771562 hasConcept C126322002 @default.
• W3006771562 hasConcept C142724271 @default.
• W3006771562 hasConcept C16685009 @default.
• W3006771562 hasConcept C168563851 @default.
• W3006771562 hasConcept C204787440 @default.
• W3006771562 hasConcept C27081682 @default.
• W3006771562 hasConcept C2777338322 @default.
• W3006771562 hasConcept C2777551382 @default.
• W3006771562 hasConcept C2777688143 @default.
• W3006771562 hasConcept C2778004101 @default.
• W3006771562 hasConcept C2778093475 @default.
• W3006771562 hasConcept C2778279030 @default.
• W3006771562 hasConcept C2779234561 @default.
• W3006771562 hasConcept C2781087480 @default.
• W3006771562 hasConcept C2908647359 @default.
• W3006771562 hasConcept C29456083 @default.
• W3006771562 hasConcept C518429986 @default.
• W3006771562 hasConcept C54355233 @default.
• W3006771562 hasConcept C55493867 @default.
• W3006771562 hasConcept C71924100 @default.
• W3006771562 hasConcept C86803240 @default.
• W3006771562 hasConcept C99454951 @default.
• W3006771562 hasConceptScore W3006771562C119060515 @default.

• next